APOC1 promotes the progression of osteosarcoma by binding to MTCH2

Li,Renjie; He,Huixian; He,Xinxin

doi:10.3892/etm.2023.11862

APOC1 promotes the progression of osteosarcoma by binding to MTCH2

Authors:
- Renjie Li
- Huixian He
- Xinxin He
View Affiliations

Affiliations: School of Nursing, Sun Yat‑Sen University, The First Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510080, P.R. China, School of Medicine, Foshan University, Foshan, Guangdong 528000, P.R. China
Published online on: February 23, 2023 https://doi.org/10.3892/etm.2023.11862
Article Number: 163
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most prevalent primary malignant bone cancer worldwide. Apolipoprotein C1 (APOC1) and mitochondrial carrier homolog 2 (MTCH2) have been identified to be upregulated during the oncogenesis and metastasis of osteosarcoma. The aim of the present study was to explore the role of APOC1 in osteosarcoma progression and the mechanisms associated with MTCH2. APOC1 and MTCH2 expression in osteosarcoma cells was assessed by reverse transcription-quantitative PCR and western blotting. Then, APOC1 was silenced to detect its effect on cell viability, proliferation and apoptosis using Cell Counting Kit‑8, a colony formation assay and TUNEL staining, respectively. Transwell and wound healing assays were used to evaluate cell invasion and migration. The interaction between APOC1 and MTCH2 as predicted by the Biological General Repository for Interaction Datasets and the Search Tool for the Retrieval of Interacting Genes/Proteins databases was verified by co‑immunoprecipitation assay. Subsequently, rescue experiments were performed to analyze the regulatory effects of APOC1 on MTCH2 in the biological behavior and Warburg effect of osteosarcoma cells. Significantly upregulated APOC1 and MTCH2 expression was found in osteosarcoma SAOS‑2 cells. APOC1 silencing attenuated cell viability, inhibited proliferation and promoted cell apoptosis, coupled with the decreased Bcl‑2 expression and increased Bax and cleaved‑caspase 3 expression. The invasive and migratory capacities of SAOS‑2 cells were also suppressed following APOC1 knockdown. Moreover, APOC1 was confirmed to interact with MTCH2 in osteosarcoma cells. MTCH2 upregulation inhibited the impacts of APOC1 deletion on the malignant behavior of osteosarcoma cells. APOC1 silencing‑induced oxidative phosphorylation elevation and Warburg effect decrease were partially restored by MTCH2 upregulation. In sum, APOC1 promoted progression of osteosarcoma by binding to MTCH2, suggesting that targeting the APOC1/MTCH2 axis may be a potential treatment of osteosarcoma.

View Figures

View References

1	Gianferante DM, Mirabello L and Savage SA: Germline and somatic genetics of osteosarcoma-connecting aetiology, biology and therapy. Nat Rev Endocrinol. 13:480–491. 2017.PubMed/NCBI View Article : Google Scholar
2	Whelan JS and Davis LE: Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol. 36:188–193. 2018.PubMed/NCBI View Article : Google Scholar
3	Zheng Y, Wang G, Chen R, Hua Y and Cai Z: Mesenchymal stem cells in the osteosarcoma microenvironment: Their biological properties, influence on tumor growth, and therapeutic implications. Stem Cell Res Ther. 9(22)2018.PubMed/NCBI View Article : Google Scholar
4	Anderson ME: Update on survival in osteosarcoma. Orthop Clin North Am. 47:283–292. 2016.PubMed/NCBI View Article : Google Scholar
5	Brewer HB Jr, Shulman R, Herbert P, Ronan R and Wehrly K: The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins. J Biol Chem. 249:4975–4984. 1974.PubMed/NCBI
6	Fuior EV and Gafencu AV: Apolipoprotein C1: Its pleiotropic effects in lipid metabolism and beyond. Int J Mol Sci. 20(5939)2019.PubMed/NCBI View Article : Google Scholar
7	Ren H, Chen Z, Yang L, Xiong W, Yang H, Xu K, Zhai E, Ding L, He Y and Song X: Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer. Cancer Manag Res. 11:4917–4930. 2019.PubMed/NCBI View Article : Google Scholar
8	Shi X, Wang J, Dai S, Qin L, Zhou J and Chen Y: Apolipoprotein C1 (APOC1): A novel diagnostic and prognostic biomarker for cervical cancer. Onco Targets Ther. 13:12881–12891. 2020.PubMed/NCBI View Article : Google Scholar
9	Guo Q, Liu XL, Jiang N, Zhang WJ, Guo SW, Yang H, Ji YM, Zhou J, Guo JL, Zhang J and Liu HS: Decreased APOC1 expression inhibited cancer progression and was associated with better prognosis and immune microenvironment in esophageal cancer. Am J Cancer Res. 12:4904–4929. 2022.PubMed/NCBI
10	Liu J, Wu S, Xie X, Wang Z and Lei Q: Identification of potential crucial genes and key pathways in osteosarcoma. Hereditas. 157(29)2020.PubMed/NCBI View Article : Google Scholar
11	Robinson AJ, Kunji ER and Gross A: Mitochondrial carrier homolog 2 (MTCH2): The recruitment and evolution of a mitochondrial carrier protein to a critical player in apoptosis. Exp Cell Res. 318:1316–1323. 2012.PubMed/NCBI View Article : Google Scholar
12	Fu D, Liu S, Liu J, Chen W, Long X, Chen X, Zhou Y, Zheng Y and Huang S: iTRAQ-based proteomic analysis of the molecular mechanisms and downstream effects of fatty acid synthase in osteosarcoma cells. J Clin Lab Anal. 35(e23653)2021.PubMed/NCBI View Article : Google Scholar
13	Yuan Q, Yang W, Zhang S, Li T, Zuo M, Zhou X, Li J, Li M, Xia X, Chen M and Liu Y: Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma. Mol Med. 27(7)2021.PubMed/NCBI View Article : Google Scholar
14	Buzaglo-Azriel L, Kuperman Y, Tsoory M, Zaltsman Y, Shachnai L, Zaidman SL, Bassat E, Michailovici I, Sarver A, Tzahor E, et al: Loss of muscle MTCH2 increases whole-body energy utilization and protects from diet-induced obesity. Cell Rep. 14:1602–1610. 2016.PubMed/NCBI View Article : Google Scholar
15	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI View Article : Google Scholar
16	Warburg O, Wind F and Negelein E: The metabolism of tumors in the body. J Gen Physiol. 8:519–530. 1927.PubMed/NCBI View Article : Google Scholar
17	Baltazar F, Afonso J, Costa M and Granja S: Lactate beyond a waste metabolite: Metabolic affairs and signaling in malignancy. Front Oncol. 10(231)2020.PubMed/NCBI View Article : Google Scholar
18	Schwartz L, Supuran CT and Alfarouk KO: The Warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem. 17:164–170. 2017.PubMed/NCBI View Article : Google Scholar
19	Zhu R, Li X and Ma Y: miR-23b-3p suppressing PGC1α promotes proliferation through reprogramming metabolism in osteosarcoma. Cell Death Dis. 10(381)2019.PubMed/NCBI View Article : Google Scholar
20	Oughtred R, Stark C, Breitkreutz BJ, Rust J, Boucher L, Chang C, Kolas N, O'Donnell L, Leung G, McAdam R, et al: The BioGRID interaction database: 2019 update. Nucleic Acids Res. 47:D529–D541. 2019.PubMed/NCBI View Article : Google Scholar
21	Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al: STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47:D607–D613. 2019.PubMed/NCBI View Article : Google Scholar
22	Livak KJ and Schmittgen TD: . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
23	Kobliakov VA: The mechanisms of regulation of aerobic glycolysis (Warburg effect) by oncoproteins in carcinogenesis. Biochemistry (Mosc). 84:1117–1128. 2019.PubMed/NCBI View Article : Google Scholar
24	Abbaszadeh Z, Çeşmeli S and Biray Avcı Ç: Crucial players in glycolysis: Cancer progress. Gene. 726(144158)2020.PubMed/NCBI View Article : Google Scholar
25	Sica V, Bravo-San Pedro JM, Stoll G and Kroemer G: Oxidative phosphorylation as a potential therapeutic target for cancer therapy. Int J Cancer. 146:10–17. 2020.PubMed/NCBI View Article : Google Scholar
26	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009.PubMed/NCBI View Article : Google Scholar
27	Jong MC, Hofker MH and Havekes LM: Role of ApoCs in lipoprotein metabolism: Functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 19:472–484. 1999.PubMed/NCBI View Article : Google Scholar
28	Jong MC, Dahlmans VE, van Gorp PJ, van Dijk KW, Breuer ML, Hofker MH and Havekes LM: In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest. 98:2259–2267. 1996.PubMed/NCBI View Article : Google Scholar
29	Muurling M, van den Hoek AM, Mensink RP, Pijl H, Romijn JA, Havekes LM and Voshol PJ: Overexpression of APOC1 in obob mice leads to hepatic steatosis and severe hepatic insulin resistance. J Lipid Res. 45:9–16. 2004.PubMed/NCBI View Article : Google Scholar
30	Poirier J, Hess M, May PC and Finch CE: Cloning of hippocampal poly(A) RNA sequences that increase after entorhinal cortex lesion in adult rat. Brain Res Mol Brain Res. 9:191–195. 1991.PubMed/NCBI View Article : Google Scholar
31	Leduc V, Jasmin-Bélanger S and Poirier J: APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol Med. 16:469–477. 2010.PubMed/NCBI View Article : Google Scholar
32	Li YL, Wu LW, Zeng LH, Zhang ZY, Wang W, Zhang C and Lin NM: ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3. Oncogene. 39:6203–6217. 2020.PubMed/NCBI View Article : Google Scholar
33	Zhang H, Wang Y, Liu C, Li W, Zhou F, Wang X and Zheng J: The Apolipoprotein C1 is involved in breast cancer progression via EMT and MAPK/JNK pathway. Pathol Res Pract. 229(153746)2022.PubMed/NCBI View Article : Google Scholar
34	Takano S, Yoshitomi H, Togawa A, Sogawa K, Shida T, Kimura F, Shimizu H, Tomonaga T, Nomura F and Miyazaki M: Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene. 27:2810–2822. 2008.PubMed/NCBI View Article : Google Scholar
35	Wang HJ, Ma YX, Wang AH, Jiang YS and Jiang XZ: Expression of apolipoprotein C1 in clear cell renal cell carcinoma: An oncogenic gene and a prognostic marker. Kaohsiung J Med Sci. 37:419–426. 2021.PubMed/NCBI View Article : Google Scholar
36	Trougakos IP, So A, Jansen B, Gleave ME and Gonos ES: Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 64:1834–1842. 2004.PubMed/NCBI View Article : Google Scholar
37	Delbridge AR, Grabow S, Strasser A and Vaux DL: Thirty years of BCL-2: Translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 16:99–109. 2016.PubMed/NCBI View Article : Google Scholar
38	Burlacu A: Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med. 7:249–257. 2003.PubMed/NCBI View Article : Google Scholar
39	Lowe SW and Lin AW: Apoptosis in cancer. Carcinogenesis. 21:485–495. 2000.PubMed/NCBI View Article : Google Scholar
40	Hu W and Xiao Z: Formononetin induces apoptosis of human osteosarcoma cell line U2OS by regulating the expression of Bcl-2, Bax and MiR-375 in vitro and in vivo. Cell Physiol Biochem. 37:933–939. 2015.PubMed/NCBI View Article : Google Scholar
41	Zhao S, Zhang Y, Lu X, Ding H, Han B, Song X, Miao H, Cui X, Wei S, Liu W, et al: CDC20 regulates the cell proliferation and radiosensitivity of P53 mutant HCC cells through the Bcl-2/Bax pathway. Int J Biol Sci. 17:3608–3621. 2021.PubMed/NCBI View Article : Google Scholar
42	Huang LL, Wang Z, Cao CJ, Ke ZF, Wang F, Wang R, Luo CQ, Lu X and Wang LT: AEG-1 associates with metastasis in papillary thyroid cancer through upregulation of MMP2/9. Int J Oncol. 51:812–822. 2017.PubMed/NCBI View Article : Google Scholar
43	Zaltsman Y, Shachnai L, Yivgi-Ohana N, Schwarz M, Maryanovich M, Houtkooper RH, Vaz FM, De Leonardis F, Fiermonte G, Palmieri F, et al: MTCH2/MIMP is a major facilitator of tBID recruitment to mitochondria. Nat Cell Biol. 12:553–562. 2010.PubMed/NCBI View Article : Google Scholar
44	Grinberg M, Schwarz M, Zaltsman Y, Eini T, Niv H, Pietrokovski S and Gross A: Mitochondrial carrier homolog 2 is a target of tBID in cells signaled to die by tumor necrosis factor alpha. Mol Cell Biol. 25:4579–4590. 2005.PubMed/NCBI View Article : Google Scholar
45	Khan DH, Mullokandov M, Wu Y, Voisin V, Gronda M, Hurren R, Wang X, MacLean N, Jeyaraju DV, Jitkova Y, et al: Mitochondrial carrier homolog 2 is necessary for AML survival. Blood. 136:81–92. 2020.PubMed/NCBI View Article : Google Scholar
46	Arigoni M, Barutello G, Riccardo F, Ercole E, Cantarella D, Orso F, Conti L, Lanzardo S, Taverna D, Merighi I, et al: miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. Am J Pathol. 182:2058–2070. 2013.PubMed/NCBI View Article : Google Scholar
47	Liu L, Chai L, Ran J, Yang Y and Zhang L: BAI1 acts as a tumor suppressor in lung cancer A549 cells by inducing metabolic reprogramming via the SCD1/HMGCR module. Carcinogenesis. 41:1724–1734. 2020.PubMed/NCBI View Article : Google Scholar
48	Wu Z, Wu J, Zhao Q, Fu S and Jin J: Emerging roles of aerobic glycolysis in breast cancer. Clin Transl Oncol. 22:631–646. 2020.PubMed/NCBI View Article : Google Scholar
49	Li L, Ji Y, Zhang L, Cai H, Ji Z, Gu L and Yang S: Wogonin inhibits the growth of HT144 melanoma via regulating hedgehog signaling-mediated inflammation and glycolysis. Int Immunopharmacol. 101(108222)2021.PubMed/NCBI View Article : Google Scholar
50	Sottnik JL, Lori JC, Rose BJ and Thamm DH: Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. Clin Exp Metastasis. 28:865–875. 2011.PubMed/NCBI View Article : Google Scholar
51	Shen S, Yao T, Xu Y, Zhang D, Fan S and Ma J: CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc. Mol Cancer. 19(151)2020.PubMed/NCBI View Article : Google Scholar
52	Zhao SJ, Shen YF, Li Q, He YJ, Zhang YK, Hu LP, Jiang YQ, Xu NW, Wang YJ, Li J, et al: SLIT2/ROBO1 axis contributes to the Warburg effect in osteosarcoma through activation of SRC/ERK/c-MYC/PFKFB2 pathway. Cell Death Dis. 9(390)2018.PubMed/NCBI View Article : Google Scholar
53	Maryanovich M, Zaltsman Y, Ruggiero A, Goldman A, Shachnai L, Zaidman SL, Porat Z, Golan K, Lapidot T and Gross A: An MTCH2 pathway repressing mitochondria metabolism regulates haematopoietic stem cell fate. Nat Commun. 6(7901)2015.PubMed/NCBI View Article : Google Scholar